MedTrace Logo

One-year Results After Single-center Water Vapor Thermal Therapy for Symptomatic Benign Prostatic Hyperplasia.

NCT06257654 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 71

Last updated 2024-02-15

No results posted yet for this study

Summary

Objective: Rezūm vapor ablation is a minimally invasive treatment for benign prostatic hyperplasia (BPH) that uses injections of sterile water vapor directly into the prostate for tissue ablation. Although Rezūm is currently indicated for use in men with prostate sizes ≥30 and ≤80 ml, it is unclear how effective Rezūm is for men in urinary retention. The investigators sought to determine whether Rezūm is effective in the treatment of catheter-dependent urinary retention secondary to BPH.

Conditions

  • Prostatic Hyperplasia

Interventions

DEVICE

REZUM

The 3rd and 12th month follow-ups of the patients who underwent REZUM operation were evaluated.

Sponsors & Collaborators

  • Hisar Intercontinental Hospital

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2022-12-31
Completion
2023-12-31
FDA Device
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06257654 on ClinicalTrials.gov